What is the primary purpose of this filing?

This filing is a Form 10-Q, a quarterly report required by the SEC. Its purpose is to provide investors with an update on Bristol Myers Squibb's financial performance and condition during the first quarter of 1998, including any significant events that may have occurred.

Does the provided text contain the company's financial results?

No, the provided text is a directory listing of the SEC filing. It does not contain the actual financial statements or detailed performance metrics of Bristol Myers Squibb. Investors will need to access the full 10-Q document to review the company's financial data.

What financial metrics should investors look for in the full 10-Q filing?

Investors should look for key financial metrics such as revenue generated, cost of goods sold, operating expenses, net income, earnings per share (EPS), cash flow from operations, and the company's balance sheet (assets, liabilities, and equity). They should also review the Management's Discussion and Analysis (MD&A) section for insights into the company's performance and outlook.

Are there any specific drugs or product lines mentioned in this snippet that are important for investors?

The provided text is a directory listing and does not mention any specific drugs, product lines, or R&D activities. To understand the company's product performance and pipeline, investors must consult the full 10-Q filing and any accompanying press releases or investor presentations from that period.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q1 FY1998

Summary

Bristol Myers Squibb Company (BMY) filed its quarterly report for the period ending March 30, 1998. This filing provides a snapshot of the company's financial performance and condition during the first quarter of 1998. Investors should pay close attention to the company's revenue streams, profitability, and any significant developments impacting its product pipeline or market position. While this filing does not contain detailed financial statements within the provided text snippet, it signifies a period of ongoing operations for a major pharmaceutical company. Key areas of interest for investors typically include updates on drug development, regulatory approvals, sales performance of key products, and any announcements regarding mergers, acquisitions, or strategic partnerships that could shape the company's future growth trajectory. Investors should seek the full filing for comprehensive financial data and management discussion.

Key Highlights

1Filing is a 10-Q for Bristol Myers Squibb Co (BMY) for the period ending March 30, 1998.
2The report was filed on May 13, 1998.
3This filing represents a routine quarterly update for investors.
4The provided text snippet is a directory listing of the filing and does not contain detailed financial data.
5Investors should refer to the complete 10-Q filing for comprehensive financial statements and management discussion.
6Key areas of interest for investors in such filings typically include revenue, profitability, product pipeline updates, and strategic developments.
7The filing indicates ongoing business operations for Bristol Myers Squibb Co. during the first quarter of 1998.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 1998

Summary

Key Highlights

Frequently Asked Questions